Proactive Investors - Run By Investors For Investors

NetScientific shares gain as Vortex makes commercialisation progress

Vortex updated on progress with its CTC capture system
NetScientific shares gain as Vortex makes commercialisation progress
cancer cells

NetScientific plc (LON:NSCI) shares nudged higher as it revealed portfolio company Vortex Biosciences had moved closer to selling its circulating tumour cell (CTC) capture system in the USA and Europe.

Vortex has registered a Class I medical device with the US FDA (Food and Drug Administration) and established a CE Mark for the proprietary technology.

NetScientific's chief executive and chairman of Vortex, Francois Martelet, said: "Both the CE Mark and FDA Class 1 registration are significant milestones achieved towards making VTX-1 commercially available in early 2017 and bringing us closer to the sale of the system in the clinical market in the US."

The CE Mark allows Vortex to install systems in the European Economic Area (EEA).

It will initially be distributed for research use only. The FDA Class 1 registration is a first step towards the sale of the system in the clinical market

The Vortex VTX-1 liquid biopsy system is a fully automated benchtop system for collecting intact CTCs.

CTCs, shed by cancer tumors, can potentially allow for better characterisation of the disease, resulting in better treatment decisions.

Cancer cells are traditionally obtained through tissue biopsies but these are costly, painful, often not possible.

Shares added 6.3% to stand at 67.5p.

Why Invest In Netscientific PLC? Read More Here

Register here to be notified of future NSCI Company articles
View full NSCI profile

Netscientific PLC Timeline

Related Articles

January 11 2017
“[We are] entering a very exciting phase, which should result in the crystallisation of substantial value,” said chief executive, Dr Satu Vainikka.
a child with asthma using an inhaler
September 22 2016
Phase II results for its prospective asthma treatment are due next year, while its LOXL2 collaboration with Pharmaxis is set for a Phase I trial in 2017
newspaper with word cancer magnified
January 30 2017
The start of 2017 has seen some good trial results for its skin cancer treatment, as well as a collaboration deal that will accelerate the development of its lung cancer drug

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use